Systemic treatments of patients developing teGVHD from the 2 largest series
| Treatments . | N = 21* . | Percentage . |
|---|---|---|
| Systemic steroids | 20 | 95 |
| Calcineurin inhibitors | 10 | 48 |
| Extracorporeal photopheresis (ECP) | 6 | 29 |
| Mycophenolate | 6 | 29 |
| Rituximab | 3 | 14 |
| ATG | 2 | 10 |
| Basiliximab | 2 | 10 |
| Sirolimus | 1 | 5 |
| Treatments . | N = 21* . | Percentage . |
|---|---|---|
| Systemic steroids | 20 | 95 |
| Calcineurin inhibitors | 10 | 48 |
| Extracorporeal photopheresis (ECP) | 6 | 29 |
| Mycophenolate | 6 | 29 |
| Rituximab | 3 | 14 |
| ATG | 2 | 10 |
| Basiliximab | 2 | 10 |
| Sirolimus | 1 | 5 |
One patient in the US study was treated with topicals only and responded. One patient in the French study died abruptly from multiorgan failure and was not treated with any systemic therapies.